Trials
Search / Trial NCT05657249

Alternative Surveillance Program for Patients With High Risk Group of HCC

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Dec 10, 2022

Trial Information

Current as of January 14, 2025

Active, not recruiting

Keywords

Us Mri Hcc Surveillance Risk Estimation

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • chronic hepatitis B or C
  • Child-Pugh classification A
  • HCC risk score \>= -2.04
  • have not diagnosed with HCC
  • on surveillance program using US and negative on previous US within 6-8 months of enrollment
  • sign informed consent
  • Exclusion Criteria:
  • younger than 40 years or older than 70 years old
  • history of HCC
  • severe GFR or on HD/PD due to renal failure
  • contra-indication of MRI
  • congestive hepatopathy
  • iron deposition
  • pregnancy or nursing mother
  • non-viral hepatitis or liver cirrhosis

Trial Officials

Jeong Hee Yoon, MD

Principal Investigator

Seoul National University Hospital

About Seoul National University Hospital

Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.

Locations

Seoul, , Korea, Republic Of

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials